One interesting development took place in February 2026. A study published in The BMJ involved 3,068 women in China and aimed to find out whether menstrual blood could be used to detect HPV, the virus responsible for almost all cases of cervical cancer.

Instead of being collected through regular cervical sampling by a healthcare worker, menstrual blood samples were gathered with the help of a special absorbent collection device.

Results looked promising: It was similar to traditional healthcare professional-collected cervical HPV screening.

And why does it matter? Because cervical screenings can be challenging, humiliating or stressful for some women. Some women also have problems with health access, disability, prior trauma or cultural factors. A trustworthy menstrual blood test will allow women to do a painless screening on their own.

HPV detection is only one research area. In 2012, experts found 1,061 proteins in menstrual blood, which made it clear that menstrual blood is unique from the molecular composition perspective. The current research revolves around the possibility of using menstrual blood in the following areas: Endometriosis and its specific markers. Hormones and reproductive health. Ovarian reserve, including AMH. Cervical cancer and HPV. Other fields with the use of the specific proteins and molecular markers.

Medical technology experts are also developing specialised tools and collection devices to make this research possible.

Spotting a promising biomarker is one thing; turning it into a clinically validated diagnostic test is quite another. Most of these applications still need plenty of further research, and menstrual blood testing isn’t ready to replace established cervical screening just yet.

However, this research is very relevant because if successfully developed and implemented, it could help numerous women by making the screening test accessible, which would prevent late diagnoses, potentially prevent cancer and most importantly, save lives.